Efficacy and Safety Study of I10E in Treatment of Patients With CIDP (PRISM)
An International, Multicentre, Efficacy and Safety Study of I10E in Initial and Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Sponsor: Laboratoire français de Fractionnement et de Biotechnologies
Listed as NCT02293460, this PHASE3 trial focuses on Chronic Inflammatory Demyelinating Polyradiculoneuropathy and remains completed. Sponsored by Laboratoire français de Fractionnement et de Biotechnologies, it has been updated 9 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Apr 2020 [monthly]
Completed PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Jan 2017 — Dec 2017 [monthly]
Recruiting PHASE3
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Laboratoire français de Fractionnement et de Biotechnologies
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ankara, Turkey (Türkiye) , Barcelona, Spain , Bordeaux, France , Bursa, Turkey (Türkiye) , Dijon, France , Genova, Italy , Istanbul, Turkey (Türkiye) , London, United Kingdom , Madrid, Spain , Manouba, Tunisia and 18 more locations